Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/BIIB
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Biogen Inc (BIIB) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Biogen (BIIB) trades at $199.15, up 0.12% on the day, with a bullish technical signal from moving averages and RSI near oversold levels at 20.73. The company reported Q1 2026 EPS of $3.57, beating estimates of $3.05, continuing a trend of earnings surprises. Revenue for 2025 was $9.89B with a net income margin of 13.81%, while recent acquisitions like RayThera for up to $1B aim to bolster its immunology pipeline. Analyst consensus price target is $226.00, implying potential upside from current levels.
BIIB presents a mixed outlook with strong earnings momentum and strategic acquisitions offset by legacy drug sales declines and legal investigations. The stock's valuation at a P/E of 21.41 is reasonable relative to growth prospects, but investors face risks from pipeline execution and competitive pressures in biotech. Near-term catalysts include Alzheimer's data presentations at AAIC 2026 in July.
Read full analysis

Key Stats

  • Market Cap
    $29.40B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $216.63
  • 52W Low
    $122.68
  • Typical Hold Time
    -
  • Enterprise Value
    $31.68B
  • Div Yield
    -
  • Trading Activity
    -
$209.18
52W Low: $122.68
21 Jul 2025
52W High: $216.63
29 Jun 2026

Track Biogen Inc (BIIB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Biogen Inc has traded between a low of $122.68 and a high of $216.63, highlighting its annual price range. Buy and sell Biogen Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Most Recent News

Content is generated by Aura AI

AI use in cybersecurity jumps to 78% in 2026, but governance and failures lag behind.

The 2026 SANS AI Survey reveals rapid AI adoption in cybersecurity, with 78% of organizations using AI, up from 50% last year. However, governance structures and formal audit frameworks have not kept pace, leading to increased AI-related failures in ...

Market News
1 hour ago
Matt Bromiley
Neutral
pluang ai news

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.

The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Market News
3 hours ago
Na
Bullish
news icon
pluang ai news

Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.

Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...

Market News
3 hours ago
Na
Bullish
news icon
pluang ai news
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $29.40B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $216.63
  • 52W Low
    $122.68
  • Typical Hold Time
    -
  • Enterprise Value
    $31.68B
  • Div Yield
    -
  • Trading Activity
    -
$209.18
52W Low: $122.68
21 Jul 2025
52W High: $216.63
29 Jun 2026

Track Biogen Inc (BIIB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Biogen Inc has traded between a low of $122.68 and a high of $216.63, highlighting its annual price range. Buy and sell Biogen Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!